These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Aryl or heteroaryl substituted aminal derivatives of HCV NS5A inhibitor MK-8742. Yu W; Coburn CA; Nair AG; Wong M; Rosenblum SB; Zhou G; Dwyer MP; Tong L; Hu B; Zhong B; Hao J; Ji T; Zan S; Kim SH; Zeng Q; Selyutin O; Chen L; Masse F; Agrawal S; Liu R; Xia E; Zhai Y; Curry S; McMonagle P; Ingravallo P; Asante-Appiah E; Lin M; Kozlowski JA Bioorg Med Chem Lett; 2016 Aug; 26(15):3414-20. PubMed ID: 27394665 [TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships of proline modifications around the tetracyclic-indole class of NS5A inhibitors. Tong L; Yu W; Coburn CA; Chen L; Selyutin O; Zeng Q; Dwyer MP; Nair AG; Shankar BB; Kim SH; Yang DY; Rosenblum SB; Ruck RT; Davies IW; Hu B; Zhong B; Hao J; Ji T; Zan S; Liu R; Agrawal S; Carr D; Curry S; McMonagle P; Bystol K; Lahser F; Ingravallo P; Chen S; Asante-Appiah E; Kozlowski JA Bioorg Med Chem Lett; 2016 Nov; 26(21):5354-5360. PubMed ID: 27680588 [TBL] [Abstract][Full Text] [Related]
4. Discovery of Chromane Containing Hepatitis C Virus (HCV) NS5A Inhibitors with Improved Potency against Resistance-Associated Variants. Yu W; Tong L; Hu B; Zhong B; Hao J; Ji T; Zan S; Coburn CA; Selyutin O; Chen L; Rokosz L; Agrawal S; Liu R; Curry S; McMonagle P; Ingravallo P; Asante-Appiah E; Chen S; Kozlowski JA J Med Chem; 2016 Nov; 59(22):10228-10243. PubMed ID: 27792320 [TBL] [Abstract][Full Text] [Related]
5. Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742. Yu W; Coburn CA; Nair AG; Wong M; Tong L; Dwyer MP; Hu B; Zhong B; Hao J; Yang DY; Selyutin O; Jiang Y; Rosenblum SB; Kim SH; Lavey BJ; Zhou G; Rizvi R; Shankar BB; Zeng Q; Chen L; Agrawal S; Carr D; Rokosz L; Liu R; Curry S; McMonagle P; Ingravallo P; Lahser F; Asante-Appiah E; Nomeir A; Kozlowski JA Bioorg Med Chem Lett; 2016 Aug; 26(15):3800-5. PubMed ID: 27282742 [TBL] [Abstract][Full Text] [Related]
6. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. Coburn CA; Meinke PT; Chang W; Fandozzi CM; Graham DJ; Hu B; Huang Q; Kargman S; Kozlowski J; Liu R; McCauley JA; Nomeir AA; Soll RM; Vacca JP; Wang D; Wu H; Zhong B; Olsen DB; Ludmerer SW ChemMedChem; 2013 Dec; 8(12):1930-40. PubMed ID: 24127258 [TBL] [Abstract][Full Text] [Related]
7. Alternative core development around the tetracyclic indole class of HCV NS5A inhibitors. Tong L; Yu W; Coburn CA; Meinke PT; Nair AG; Dwyer MP; Chen L; Selyutin O; Rosenblum SB; Jiang Y; Fells J; Hu B; Zhong B; Soll RM; Liu R; Agrawal S; Xia E; Zhai Y; Kong R; Ingravallo P; Nomeir A; Asante-Appiah E; Kozlowski JA Bioorg Med Chem Lett; 2016 Oct; 26(20):5132-5137. PubMed ID: 27634194 [TBL] [Abstract][Full Text] [Related]
8. The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons. Lahser FC; Bystol K; Curry S; McMonagle P; Xia E; Ingravallo P; Chase R; Liu R; Black T; Hazuda D; Howe AY; Asante-Appiah E Antimicrob Agents Chemother; 2016 May; 60(5):2954-64. PubMed ID: 26926625 [TBL] [Abstract][Full Text] [Related]
9. Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons. Asante-Appiah E; Curry S; McMonagle P; Ingravallo P; Chase R; Nickle D; Qiu P; Howe A; Lahser FC Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416549 [TBL] [Abstract][Full Text] [Related]
10. Design and evaluation of novel tetracyclic benzofurans as palm site allosteric inhibitors of HCV NS5B polymerase. Liu H; Dai X; He S; Brockunier L; Marcantonio K; Ludmerer SW; Li F; Feng KI; Nargund RP; Palani A Bioorg Med Chem Lett; 2019 Dec; 29(24):126104. PubMed ID: 30389294 [TBL] [Abstract][Full Text] [Related]
11. Discovery of novel pan-genotypic HCV NS5A inhibitors containing a novel tetracyclic core. Yu W; Hu B; Zhong B; Hao J; Lei Z; Agrawal S; Rokosz L; Liu R; Chen S; Asante-Appiah E; Kozlowski JA Bioorg Med Chem Lett; 2019 Mar; 29(5):700-706. PubMed ID: 30711390 [TBL] [Abstract][Full Text] [Related]
12. Matched and mixed cap derivatives in the tetracyclic indole class of HCV NS5A inhibitors. Dwyer MP; Keertikar KM; Chen L; Tong L; Selyutin O; Nair AG; Yu W; Zhou G; Lavey BJ; Yang DY; Wong M; Kim SH; Coburn CA; Rosenblum SB; Zeng Q; Jiang Y; Shankar BB; Rizvi R; Nomeir AA; Liu R; Agrawal S; Xia E; Kong R; Zhai Y; Ingravallo P; Asante-Appiah E; Kozlowski JA Bioorg Med Chem Lett; 2016 Aug; 26(16):4106-11. PubMed ID: 27423481 [TBL] [Abstract][Full Text] [Related]
13. Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms. Tong L; Yu W; Chen L; Selyutin O; Dwyer MP; Nair AG; Mazzola R; Kim JH; Sha D; Yin J; Ruck RT; Davies IW; Hu B; Zhong B; Hao J; Ji T; Zan S; Liu R; Agrawal S; Xia E; Curry S; McMonagle P; Bystol K; Lahser F; Carr D; Rokosz L; Ingravallo P; Chen S; Feng KI; Cartwright M; Asante-Appiah E; Kozlowski JA J Med Chem; 2017 Jan; 60(1):290-306. PubMed ID: 27808515 [TBL] [Abstract][Full Text] [Related]
14. Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study. Palladino C; Sánchez-Carrillo M; Mate-Cano I; Vázquez-Morón S; Jimenez-Sousa MÁ; Gutiérrez-Rivas M; Resino S; Briz V Sci Rep; 2017 Jun; 7(1):2892. PubMed ID: 28588311 [TBL] [Abstract][Full Text] [Related]
15. Evolutionary pathways to NS5A inhibitor resistance in genotype 1 hepatitis C virus. Zhou S; Williford SE; McGivern DR; Burch CL; Hu F; Benzine T; Ingravallo P; Asante-Appiah E; Howe AYM; Swanstrom R; Lemon SM Antiviral Res; 2018 Oct; 158():45-51. PubMed ID: 30081054 [TBL] [Abstract][Full Text] [Related]
16. Development of a New Structural Class of Broadly Acting HCV Non-Nucleoside Inhibitors Leading to the Discovery of MK-8876. McComas CC; Palani A; Chang W; Holloway MK; Lesburg CA; Li P; Liverton N; Meinke PT; Olsen DB; Peng X; Soll RM; Ummat A; Wu J; Wu J; Zorn N; Ludmerer SW ChemMedChem; 2017 Sep; 12(17):1436-1448. PubMed ID: 28741898 [TBL] [Abstract][Full Text] [Related]
17. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication. Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of antiviral effects of novel NS5A inhibitors in hepatitis C virus cell culture system with full-genome infectious clones. Murayama A; Fujiwara K; Yamada N; Shiina M; Aly HH; Masaki T; Muramatsu M; Wakita T; Kato T Antiviral Res; 2018 Oct; 158():161-170. PubMed ID: 30118732 [TBL] [Abstract][Full Text] [Related]
19. Preclinical and Clinical Resistance Profile of EDP-239, a Novel Hepatitis C Virus NS5A Inhibitor. Owens CM; Brasher BB; Polemeropoulos A; Rhodin MH; McAllister N; Wong KA; Jones CT; Jiang L; Lin K; Or YS Antimicrob Agents Chemother; 2016 Oct; 60(10):6216-26. PubMed ID: 27503644 [TBL] [Abstract][Full Text] [Related]
20. Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice. Doi A; Hikita H; Kai Y; Tahata Y; Saito Y; Nakabori T; Yamada R; Kodama T; Sakamori R; Murayama A; Nitta S; Asahina Y; Suemizu H; Tatsumi T; Kato T; Takehara T J Gastroenterol; 2019 May; 54(5):449-458. PubMed ID: 30684016 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]